|
Interrogating immune signatures in the thoracic duct of patients with multiple sclerosis |
1F31AI167501-01 |
|
NIAID |
2022 |
|
Prosthetic Joint Infection After Primary Total Knee Arthroplasty: Incidence, Microbiology and Risk Factors |
1F32AI164809-01A1 |
|
NIAID |
2022 |
|
Implant Biofilm Mediated Immune Response |
1R01AI165958-01A1 |
|
NIAID |
2022 |
|
Mechanistic and functional dissection of inflammaging in Down syndrome |
1R01AI166835-01A1 |
|
NIAID |
2022 |
|
Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course |
1R01AI169070-01A1 |
|
NIAID |
2022 |
|
Monitoring Treatment Efficacy in Leprosy |
1R21AI171254-01 |
|
NIAID |
2022 |
|
Novel Biofilm Paradigm Explaining Clinical Implant-Associated Illness. |
1R21AI171932-01 |
|
NIAID |
2022 |
|
Nanoimmunotherapy for chronic immune-mediated diseases |
1R41AI170413-01 |
|
NIAID |
2022 |
|
Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis |
1R43AI157674-01A1 |
|
NIAID |
2022 |
|
Targeted in vivo perturbation for dissecting tissue immune responses |
2U19AI128949-06 |
|
NIAID |
2022 |